Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?

13
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

This issue comes up frequently in our combined ILD/Rheumatology clinic and my pulmonary colleagues are typically looking at me for an answer as to whether I think the biomarkers are relevant to the patient's ILD. Low-level ANAs and RFs are not uncommon in the general population and can result in ove...

In a patient with SJIA who has been stable on Anakinra however is now planning to conceive or becomes pregnant, would you consider switching to Cimzia?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Chicago

As a medpeds rheumatologist who specializes in pregnancy, would ask you to please not switch this patient's medication.Cimzia will not control the systemic aspects of the sJIA. Flaring is dangerous, particularly in pregnancy, can trigger MAS, and may lead to needing systemic steroids or even needing...

What role do you see for JAK inhibitors in RA treatment strategies given the data we now have regarding CV and cancer outcomes?

4 Answers

Mednet Member
Mednet Member
Rheumatology · Mayo

The outcomes of the ORAL Surveillance study (Ytterberg et al., PMID 35081280) will surely affect guideline recommendations as they have already led to changes to the FDA-approved labels of all JAK inhibitors approved for the treatment of RA, which now state that they are indicated for patients who h...

Would you uptitrate methotrexate dosing when a patient flares on a TNFi and methotrexate 15 mg weekly?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · Washington University Physicians

For mild to moderately low flare of disease, I would up-titrate methotrexate if no history of prior adverse effects at higher doses in the setting of normal renal function and no other medical comorbidities of concern. Many authors would still consider optimized dosing of methotrexate to be 20 to 25...

How do you envision incorporating CAR-T therapy into your clinical practice?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · Cleveland Clinic

This is an excellent question—one that, for now, might best be explored over a glass of white wine and some lively hand-waving. It’s a question I often find myself reflecting on every time I hear a presentation or read a new paper on the subject. Here’s a brief editorial response outlining how I env...

Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Northwestern University Feinberg School of Medicine

At this point, I do not see this as an issue. The increased risk seen with IL17 inhibitors is overwhelmingly oral candidiasis and not candidiasis elsewhere, or other fungal infections. In the clinical trials, this risk seems to be higher with bimekizumab than with secukinumab or ixekizumab, which ma...

How do you approach managing nausea and GI side effects when initiating methotrexate?

6
5 Answers

Mednet Member
Mednet Member
Rheumatology · University of Cincinnati

There are several strategies to minimize nausea and gastrointestinal symptoms with the use of methotrexate. The medication can be taken with food, just not with caffeine. The dose can be split throughout the day it is taken such as half the dose in the morning and the other half in the evening. The ...

How do you approach management of recurrent idiopathic pleuropericarditis?

1 Answers

Mednet Member
Mednet Member
Cardiology · NYU Grossman School of Medicine

The first line is colchicine and NSAIDs until the pain resolves, CRP normalizes, etc… After this, if the CRP tracks with the symptoms, fluid reaccumulation, and/or cMRI evidence of the pericarditis, I find il-1 inhibitors work very well.

Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?

3
1 Answers

Mednet Member
Mednet Member
Dermatology · Johns Hopkins Timeshare Practice

Can certainly help when patients have conditions that trigger Raynaud's. If otherwise healthy, I discuss keeping the extremities protected from excessive cooling.

How do you approach interpreting a low titer dsDNA (such as crithidia 1:40 to 1:80) in the setting of a moderately elevated ANA without other specific features of SLE?

5
2 Answers

Mednet Member
Mednet Member
Rheumatology · Berkshire Health Systems

Serologies are not a diagnosis nor are they diagnostic. This patient does not NOW have lupus. Are there first-degree relatives with SLE? Does this patient have any other autoimmune disorders like Hashimoto thyroiditis? What to do? Follow-up and education. Routine follow-up and welcome phone calls to...